Targeting the RIP1/RIP3 pathway has been demonstrated to be a potential therapeutic option in other neurodegenerative diseases (e.g., Gaucher,22 Huntington23) as well as in a rodent stroke models.47, 48 In this paper, we demonstrate that necroptosis is involved in the NPC1 pathogenic cascade, and our data indicate that inhibition of RIP1 may have a therapeutic role in treating patients with NPC. This evidence concerns the gene RIPK1 and Stroke.